LILRA3: A Promising Drug Target and Biomarker for Cancer (G11026)

Target Name: LILRA3

NCBI ID: G11026

LILRA3

LILRA3: A Promising Drug Target and Biomarker for Cancer

LILRA3 (Leucine-rich repeat-containing G protein-coupled receptor 3) is a protein that is expressed in various tissues and cells throughout the body. It is a member of the G protein-coupled receptor (GPCR) family, which is a large family of transmembrane proteins that play an important role in cellular signaling. LILRA3 is characterized by the presence of a leucine-rich repeat, which is a common structural motif that is found in a variety of proteins that are involved in signaling pathways.

One of the functions of LILRA3 is to participate in the regulation of cellular signaling pathways that are involved in processes such as cell growth, differentiation, and survival. LILRA3 has been shown to play a role in the regulation of cell proliferation and has been shown to be involved in the development of various types of cancer.

In addition to its role in cellular signaling, LILRA3 is also of interest as a potential drug target. The use of small molecules, such as drugs that bind specifically to LILRA3, has been shown to be a powerful tool for the development of new treatments for a variety of diseases. By targeting LILRA3, researchers can hope to disrupt the signaling pathways that are involved in the development and progression of many different diseases, including cancer.

One of the challenges in the development of new treatments for cancer is the ability to target specific and reliable drug targets. This is because the signaling pathways that are involved in cancer development are often complex and can be difficult to disrupt. LILRA3 is thought to be a promising drug target because it is involved in the regulation of a wide range of cellular processes, which makes it difficult to predict the effects of any potential treatments.

In addition to its potential as a drug target, LILRA3 is also of interest as a biomarker. The use of biomarkers, such as proteins that are derived from bodily tissues, can be a powerful tool for the diagnosis and prognosis of many different diseases. LILRA3 is thought to be a potential biomarker for a variety of diseases, including cancer.

Research into LILRA3 is still in its early stages, but it is an exciting area of study because of its potential as a drug target and as a biomarker. The use of small molecules, such as drugs that bind specifically to LILRA3, is likely to be an important tool for the development of new treatments for a variety of diseases. As research continues, it is likely that we will learn more about the role of LILRA3 in cellular signaling and its potential as a drug target and biomarker.

Protein Name: Leukocyte Immunoglobulin Like Receptor A3

Functions: Acts as soluble receptor for class I MHC antigens. Binds both classical and non-classical HLA class I molecules but with reduced affinities compared to LILRB1 or LILRB2. Binds with high affinity to the surface of monocytes, leading to abolish LPS-induced TNF-alpha production by monocytes

The "LILRA3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LILRA3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets